647 related articles for article (PubMed ID: 15996478)
21. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
22. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
23. Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle.
Liu D; Yao S; Wise GE
Eur J Oral Sci; 2006 Feb; 114(1):42-9. PubMed ID: 16460340
[TBL] [Abstract][Full Text] [Related]
24. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
25. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
[TBL] [Abstract][Full Text] [Related]
26. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
27. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK.
Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH
Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696
[TBL] [Abstract][Full Text] [Related]
28. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors.
Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ
Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856
[TBL] [Abstract][Full Text] [Related]
29. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
[TBL] [Abstract][Full Text] [Related]
30. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
31. Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor.
Chang K; Chang WH; Huang S; Huang S; Shih C
J Orthop Res; 2005 Nov; 23(6):1308-14. PubMed ID: 15913941
[TBL] [Abstract][Full Text] [Related]
32. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
33. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
34. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
Ishizuka K; Hirukawa K; Nakamura H; Togari A
Neurosci Lett; 2005 Apr; 379(1):47-51. PubMed ID: 15814197
[TBL] [Abstract][Full Text] [Related]
36. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
Bock O; Loch G; Schade U; Büsche G; Wasielewski R; Wiese B; Kreipe H
Br J Haematol; 2005 Jul; 130(1):76-82. PubMed ID: 15982347
[TBL] [Abstract][Full Text] [Related]
37. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms.
Weitzmann MN; Cenci S; Rifas L; Haug J; Dipersio J; Pacifici R
J Bone Miner Res; 2001 Feb; 16(2):328-37. PubMed ID: 11204433
[TBL] [Abstract][Full Text] [Related]
38. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
[TBL] [Abstract][Full Text] [Related]
39. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
[TBL] [Abstract][Full Text] [Related]
40. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2.
Tsuji K; Uno K; Zhang GX; Tamura M
J Bone Miner Metab; 2004; 22(2):94-103. PubMed ID: 14999519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
